𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Amplification ofESR1may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer

✍ Scribed by Kirsten Vang Nielsen; Bent Ejlertsen; Sven Müller; Susanne Møller; Birgitte B. Rasmussen; Eva Balslev; Anne-Vibeke Lænkholm; Peer Christiansen; Henning T. Mouridsen

Publisher
Springer US
Year
2010
Tongue
English
Weight
585 KB
Volume
127
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors of early distant recu
Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy : Results of a retrospective analysis
✍ Marc Debled; Gaëtan MacGrogan; Véronique Brouste; Simone Mathoulin-Pelissier; Mi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Current adjuvant hormone therapy in postmenopausal women with breast cancer is debatable between upfront aromatase inhibitors (AIs) and sequential treatment with tamoxifen. A major concern is the higher rate of early recurrences observed with sequential treatment. The aut

Comparison of anastrozole versus tamoxif
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial
✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br